Fig. 4
From: Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025
Public spending on the top 25 drugs in Canada during 2020. Historical data were collected for the top 25 drugs in Canada during 2020 (costs in millions of Canadian dollars) to examine the number of drugs for rare diseases (DRDs) in this list. Despite the high per-patient costs of DRDs, only 1 of the top 25 drugs was a DRD (SOLIRIS®, eculizumab) and its annual cost was dwarfed by the costs of drugs for more common conditions